Europe Rejects Alzheimer’s Drug Leqembi

Published on July 26, 2024

The European Union’s drugs regulator has rejected Eisai and Biogen’s Leqembi treatment for early Alzheimer’s disease, saying the risk of serious brain swelling did not outweigh its small impact on slowing cognitive decline. The decision is a blow to the companies as the drug…

Read Full Article (External Site)